Threshold Announces Webcast of Analyst Event on Sunday, June 1,
2014
Clinical Experts to Discuss TH-302 Presentations Given at
ASCO
SOUTH SAN FRANCISCO, CA--(Marketwired - May 27, 2014) -
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that
the company will webcast its analyst event with clinical experts to
be held on Sunday, June 1, 2014, from 6:00 PM to 7:30 PM Central
Time at the Four Seasons Hotel Chicago. The event will include
presentations highlighting data on TH-302, the company's
investigational hypoxia-activated prodrug, to be presented at the
50th Annual Meeting of the American Society of Clinical Oncology
(ASCO), taking place May 30 - June 3, 2014, in Chicago,
Illinois.
Guest speakers scheduled to give presentations at Threshold's
analyst event include clinical experts Dr. Paul G. Richardson,
Clinical Program Leader, Director of Clinical Research, Jerome
Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, R.J.
Corman Professor of Medicine, Harvard Medical School, Boston,
Massachusetts, and Dr. Andrew J. Brenner, Clinical Investigator
with the Institute for Drug Development at the Cancer Therapy &
Research Center at The University of Texas Health Science Center at
San Antonio, Texas. Dr. Richardson is a clinical investigator on
Threshold's Phase 1/2 trial of TH-302 in patients with advanced
multiple myeloma. Dr. Brenner is the Principal Investigator of a
Phase 1/2 Investigator-Sponsored Trial of TH-302 in patients with
bevacizumab-refractory glioblastoma.
The event is open to investors and analysts. Threshold invites
the public and the media to listen to the presentations via the
live webcast, which will be available under Webcasts in the
Investors section of www.thresholdpharm.com or can be accessed
using the following link:
http://psav.adobeconnect.com/thresholdpharmaceuticals/. The
presentations are scheduled to begin at approximately 6:15 PM
Central Time. A replay of the presentations will be archived on the
site for 30 days.
Analyst Event Details:
Date: Sunday, June 1, 2014 Time: 6:00 PM - 7:30 PM Central Time
Location: Four Seasons Hotel Chicago, 120 East Delaware Place,
Walton Room
Please RSVP to lhansen@thresholdpharm.com.
TH-302 ASCO Poster Details:
Abstract #2029 (Poster #20): Phase 1/2 study of investigational
hypoxia-targeted drug, TH-302, and bevacizumab in recurrent
glioblastoma following bevacizumab failure; Poster Highlights
Session on Central Nervous System Tumors, 1:00 PM - 4:00 PM Central
Time, Friday, May 30, 2014, Room E354b; Discussion follows, 4:30 PM
- 5:45 PM, Room E450.
Abstract #8534 (Poster #14): Preliminary safety and efficacy of
TH-302, an investigational hypoxia-targeted drug, and dexamethasone
in patients with relapsed/refractory multiple myeloma; Poster
Highlights Session on Lmyphoma and Plasma Cell Disorders, 1:00 PM -
4:00 PM Central Time, Friday, May 30, 2014, in Room S405;
Discussion follows, 4:30 PM - 5:45 PM, Room S406.
About TH-302
TH-302 is an investigational hypoxia-activated prodrug that is
designed to be activated under tumor hypoxic conditions, a hallmark
of many cancers. Areas of low oxygen levels (hypoxia) in solid
tumors are due to insufficient blood supply as a result of aberrant
vasculature. Similarly, the bone marrow of patients with
hematological malignancies has also been shown, in some cases, to
be severely hypoxic.
TH-302 is currently under evaluation in two Phase 3 trials: one
in combination with doxorubicin versus doxorubicin alone in
patients with soft tissue sarcoma, and the other in combination
with gemcitabine versus gemcitabine and placebo in patients with
advanced pancreatic cancer (MAESTRO). Both Phase 3 trials are being
conducted under Special Protocol Agreements with the U.S. Food and
Drug Administration (FDA). The FDA and the European Commission have
granted TH-302 Orphan Drug Designations for the treatment of soft
tissue sarcoma and pancreatic cancer. TH-302 is also being
investigated in earlier-stage clinical trials of other solid tumors
and hematological malignancies, in combination with chemotherapy
and antiangiogenic therapy, and for certain cancers, is being
investigated as a monotherapy.
Threshold has a global license and co-development agreement for
TH-302 with Merck KGaA, Darmstadt, Germany, which includes an
option for Threshold to co-commercialize in the U.S.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company
focused on the discovery and development of drugs targeting tumor
hypoxia, the low oxygen condition found in microenvironments of
most solid tumors as well as the bone marrows of some hematologic
malignancies. This approach offers broad potential to treat a
variety of cancers. By selectively targeting tumor cells, we are
building a pipeline of drugs that hold promise to be more effective
and less toxic to healthy tissues than conventional anticancer
drugs. For additional information, please visit our website
(www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this
press release are forward-looking statements, including statements
regarding the potential therapeutic uses and benefits of TH-302.
These statements involve risks and uncertainties that can cause
actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to: the ability of Threshold and Merck
KGaA, Darmstadt, Germany, to enroll or complete TH-302 clinical
trials; the time and expense required to conduct such clinical
trials and analyze data; issues arising in the regulatory or
manufacturing process and the results of such clinical trials
(including product safety issues and efficacy results); the risk
that preclinical studies in animal models of disease may not
accurately predict the result of human clinical trials of TH-302;
Threshold's and Merck KGaA's (Darmstadt, Germany) dependence on
single source suppliers, including the risk that these single
source suppliers may be unable to meet clinical supply demands for
TH-302 which could significantly delay the development of TH-302;
risks related to Threshold's dependence on its collaborative
relationship with Merck KGaA, Darmstadt, Germany, including its
dependence on decisions by Merck KGaA, Darmstadt, Germany regarding
the amount and timing of resource expenditures for the development
of TH-302; and Threshold's need for and the availability of
resources to develop TH-302 and to support Threshold's operations.
Further information regarding these and other risks is included
under the heading "Risk Factors" in Threshold's Quarterly Report on
Form 10-Q, which has been filed with the Securities and Exchange
Commission on May 1, 2014 and is available from the SEC's website
(www.sec.gov) and on our website (www.thresholdpharm.com) under the
heading "Investors." We undertake no duty to update any
forward-looking statement made in this news release.
Contact Laura Hansen, Ph.D. Senior Director, Corporate
Communications Phone: 650-474-8206 E-mail:
lhansen@thresholdpharm.com
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2024 to May 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From May 2023 to May 2024